ARWR ARROWHEAD PHARMACEUTICALS IN revenue, earnings and financials
For the quarter ended June 30, 2026, ARROWHEAD PHARMACEUTICALS IN reported revenue of $75.3M (up 171.0% from a year earlier), net income of −$194M and diluted EPS of −$1.36; over the last four quarters revenue was $669M and net income −$320M; for the fiscal year ended September 2025 revenue was $829M, up 23258.2% on the year before.
ARWR annual revenue and earnings
- Fiscal year ended Sep 2025: revenue $829M, gross profit n/a, operating income $98.3M, net income −$1.63M (margin -0.2%), EPS −$0.01
- Fiscal year ended Sep 2024: revenue $3.55M, gross profit n/a, operating income −$601M, net income −$599M (margin -16882.4%), EPS −$5.00
- Fiscal year ended Sep 2023: revenue $241M, gross profit n/a, operating income −$205M, net income −$205M (margin -85.3%), EPS −$1.92
- Fiscal year ended Sep 2022: revenue $243M, gross profit n/a, operating income −$179M, net income −$176M (margin -72.4%), EPS −$1.67
- Fiscal year ended Sep 2021: revenue $138M, gross profit n/a, operating income −$149M, net income −$141M (margin -101.9%), EPS −$1.36
ARWR quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $75.3M (up 171.0% year over year), net income −$194M, EPS −$1.36
- Quarter ended Mar 31, 2026: revenue $73.7M (down 86.4% year over year), net income −$133M, EPS −$0.93
- Quarter ended Dec 31, 2025: revenue $264M (up 10461.3% year over year), net income $30.8M, EPS $0.22
- Quarter ended Sep 30, 2025 (from the annual report): revenue $256M, net income −$23.8M, EPS −$0.11
- Quarter ended Jun 30, 2025: revenue $27.8M, net income −$175M, EPS −$1.26
- Quarter ended Mar 31, 2025: revenue $543M, net income $370M, EPS $2.75
- Quarter ended Dec 31, 2024: revenue $2.50M (down 29.6% year over year), net income −$173M, EPS −$1.39
- Quarter ended Sep 30, 2024 (from the annual report): revenue $0 (down 100.0% year over year), net income −$171M, EPS −$1.36
- Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income −$171M, EPS −$1.38
- Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$125M, EPS −$1.02
- Quarter ended Dec 31, 2023: revenue $3.55M (down 94.3% year over year), net income −$133M, EPS −$1.24
- Quarter ended Sep 30, 2023 (from the annual report): revenue $16.1M (down 49.0% year over year), net income −$110M, EPS −$1.02
- Quarter ended Jun 30, 2023: revenue $15.8M (down 51.2% year over year), net income −$103M, EPS −$0.96
- Quarter ended Mar 31, 2023: revenue $146M (down 3.6% year over year), net income $48.7M, EPS $0.45
- Quarter ended Dec 31, 2022: revenue $62.5M (up 127.9% year over year), net income −$41.3M, EPS −$0.39
- Quarter ended Sep 30, 2022 (from the annual report): revenue $31.6M, net income −$85.5M, EPS −$0.80
- Quarter ended Jun 30, 2022: revenue $32.4M (down 29.4% year over year), net income −$72.0M, EPS −$0.68
- Quarter ended Mar 31, 2022: revenue $152M (up 362.7% year over year), net income $44.4M, EPS $0.41
- Quarter ended Dec 31, 2021: revenue $27.4M, net income −$62.9M, EPS −$0.60
- Quarter ended Jun 30, 2021: revenue $45.9M, net income −$29.9M, EPS −$0.29
ARWR cash flow, buybacks and dividends
- Fiscal year ended Sep 2025: operating cash flow $180M, share buybacks n/a
- Fiscal year ended Sep 2024: operating cash flow −$463M, share buybacks n/a
- Fiscal year ended Sep 2023: operating cash flow −$154M, share buybacks n/a
- Fiscal year ended Sep 2022: operating cash flow −$136M, share buybacks n/a
- Fiscal year ended Sep 2021: operating cash flow $171M, share buybacks n/a
ARWR balance sheet
- Jun 30, 2026: cash n/a, total assets $2.11B, total liabilities n/a, shareholders' equity $466M
- Mar 31, 2026: cash n/a, total assets $2.27B, total liabilities n/a, shareholders' equity $614M
- Dec 31, 2025: cash n/a, total assets $1.60B, total liabilities n/a, shareholders' equity $568M
- Sep 30, 2025: cash n/a, total assets $1.39B, total liabilities n/a, shareholders' equity $466M
- Jun 30, 2025: cash n/a, total assets $1.38B, total liabilities n/a, shareholders' equity $522M
- Mar 31, 2025: cash n/a, total assets $1.57B, total liabilities n/a, shareholders' equity $683M
- Dec 31, 2024: cash n/a, total assets $1.01B, total liabilities n/a, shareholders' equity $52.6M
- Sep 30, 2024: cash n/a, total assets $1.14B, total liabilities n/a, shareholders' equity $185M
What is ARWR's revenue?
ARROWHEAD PHARMACEUTICALS IN reported $669M of revenue over its last four quarters, through June 30, 2026.
Is ARWR profitable?
No. ARROWHEAD PHARMACEUTICALS IN lost $320M over the last four quarters.
What is ARWR's EPS?
Diluted earnings per share over the last four quarters were −$2.18; −$1.36 in the latest quarter.